Diasorin LIAISON SARS-CoV-2 TrimericS IgG

Country: Singapore

Language: English

Source: HSA (Health Sciences Authority)

Available from:

SPD SCIENTIFIC PTE LTD

Class:

Class D medical device

Manufactured by:

DiaSorin, Inc.

Therapeutic area:

Immunology

Therapeutic indications:

The LIAISON® SARS-CoV-2 TrimericS IgG assay uses chemiluminescence immunoassay (CLIA) technology for the quantitative determination of anti- trimeric spike protein specific IgG antibodies to SARS-CoV-2 in human serum or plasma samples. The assay is intended as an aid in the diagnosis of CoVID-19 and to support the study of the immune status of infected patients and to assess IgG response against SARS-CoV-2 in vaccine recipients, by providing an indication of the presence of neutralizing IgG antibodies against SARS-CoV-2. Results from the LIAISON® SARS-CoV-2 TrimericS IgG assay should not be used as the sole basis to diagnose or exclude SARS-CoV-2 infection or to inform about infection status

Product summary:

Models: LIAISON® SARS-CoV-2 TrimericS IgG - 311510, LIAISON® SARS-CoV-2 TrimericS IgG Control Set - 311511, LIAISON® TrimericS IgG Diluent Accessory - 311512

Authorization date:

2022-05-23